Mesoblast Limited filed several announcements with the Australian Securities Exchange on July 14, 2026, including a new issue announcement, notifications of cessation of securities, and applications for quotation of securities. The filing incorporates multiple Appendix forms (3H, 3G, 2A, 3Y) regarding equity securities and director interests. Mesoblast Limited is a biotechnology company focused on cell therapies.
